Ratings by Citi (Robyn Karnauskas)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/22/2020 | Gilead Sciences | GILD | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2020 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/22/2020 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2019 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 7/31/2019 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 5/23/2019 | Amgen | AMGN | Upgrade | Buy (Neutral) |
169.69 (442.36) |
160.69% | Details | |
| 5/23/2019 | Gilead Sciences | GILD | Upgrade | Buy (Neutral) |
66.52 (147.60) |
121.89% | Details | |
| 5/23/2019 | Amgen | AMGN | Upgrade | Buy (Neutral) |
169.69 (169.69) |
0% | Details | |
| 5/23/2019 | Gilead Sciences | GILD | Upgrade | Buy (Neutral) |
66.52 (66.52) |
0% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
320.59 (232.92) |
-27.35% | Details | |
| 3/11/2019 | Cellectis | CLLS | Maintain | Neutral (N/A) |
|
Details | ||
| 3/5/2019 | Harpoon Therapeutics | HARP | New Coverage | Buy (N/A) |
16.20 (11.60) |
-28.4% | Details | |
| 2/27/2019 | Epizyme | EPZM | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2019 | Kadmon Holdings | KDMN | Upgrade | Buy (Neutral) |
2.52 (9.50) |
276.98% | Details | |
| 2/12/2019 | Gilead Sciences | GILD | Downgrade | Neutral (Buy) |
67.47 (66.52) |
-1.41% | Details | |
| 2/6/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 2/5/2019 | Gilead Sciences | GILD | Maintain | Buy (Buy) |
|
Details | ||
| 1/31/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/22/2019 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/7/2019 | Epizyme | EPZM | Maintain | Buy (N/A) |
|
Details | ||
| 12/17/2018 | Celgene | CELG | Maintain | Neutral (N/A) |
|
Details | ||
| 11/7/2018 | Regeneron Pharma | REGN | Maintain | Neutral (N/A) |
|
Details | ||
| 11/1/2018 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 10/25/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 10/8/2018 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/1/2018 | Amgen | AMGN | Maintain | Neutral (N/A) |
|
Details | ||
| 9/25/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2018 | Dicerna Pharmaceuticals | DRNA | Maintain | Buy (N/A) |
|
Details | ||
| 9/24/2018 | Epizyme | EPZM | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2018 | Dicerna Pharmaceuticals | DRNA | New Coverage | Buy (N/A) |
16.15 (11.60) |
-28.17% | Details | |
| 9/4/2018 | Tocagen Inc. | TOCA | New Coverage | Buy (N/A) |
9.75 (4.32) |
-55.69% | Details | |
| 8/29/2018 | Tesaro | TSRO | Maintain | Neutral (N/A) |
|
Details |
